Kelly Jayne McCann on Muck Rack

Kelly Jayne McCann

As seen in: HMP Global Learning Network, OncLive, FantasyLabs, Phillips County News

Get in touch with Kelly Jayne

Contact Kelly Jayne, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Moving Beyond Chemotherapy in Metastatic Triple-Negative Breast Cancer (mTNBC): Are We Clinically Ready? Round 2

|
By Kelly Jayne McCann, Seth Wander MD, Jason A. Mouabbi
| HMP Global Learning Network
Imlunestrant Demonstrates Favorable Safety Alone and With Abemaciclib in Advanced Breast Cancer Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer. Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Open in Who Shared View Duplicates (2) Issue with article?

Moving Beyond Chemotherapy in Metastatic Triple-Negative Breast Cancer (mTNBC): Are We Clinically Ready? Round 3

|
By Kelly Jayne McCann, Seth Wander MD, Jason A. Mouabbi
| HMP Global Learning Network
Videos
Open in Who Shared Issue with article?
|
By Kelly Jayne McCann, Seth Wander MD, Jason A. Mouabbi
| HMP Global Learning Network
Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype with poor prognosis that has historically relied on chemotherapy due to a lack of targeted treatment options. In this debate, experts examine whether emerging data on antibody-drug conjugates (ADCs), including sacituzumab govitecan, support a shift away from a chemotherapy-first approach and how these agents can be effectively integrated into clinical practice.
Open in Who Shared Issue with article?
See all 20 licensed articles (24 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified